NCT07230483招募中2 期
An Open-Label, Multicenter Study to Evaluate Long-Term Safety and Efficacy of CM512 in Atopic Dermatitis Patients.
Keymed Biosciences Co.Ltd1 个研究点 分布在 1 个国家目标入组 246 人开始时间: 2025年12月1日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 246
- 试验地点
- 1
- 主要终点
- Adverse events
研究概览
简要总结
This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).
- •Subjects who have completed the week 18 evaluation in the parent study CM512-101102 or the End of Study(EOS) visit in the parent study CM512-100001.
排除标准
- •Not enough washing-out period for previous therapy.
- •Any other condition assessed by the investigator that makes participants unsuitable for participation in this study.
研究组 & 干预措施
Group 1
Experimental
干预措施: CM512 (Biological)
Group 2
Experimental
干预措施: CM512 (Biological)
Group 3
Experimental
干预措施: CM512 (Biological)
Group 4
Experimental
干预措施: CM512 (Biological)
结局指标
主要结局
Adverse events
时间窗: up to 52 weeks
The incidence of adverse events
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Tofogliflozin GLP-1 Analogue Combination TrialType 2 Diabetes MellitusNCT02537834Kowa Company, Ltd.65
已完成
2 期
A Study of CM310 in Subjects With Moderate-to-Severe Atopic DermatitisAtopic DermatitisNCT06116565Keymed Biosciences Co.Ltd263
已完成
3 期
Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With SchizophreniaSchizophreniaNCT00640601AstraZeneca331
已完成
3 期
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesNCT04164199BeOne Medicines404
已完成
3 期
Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00389415Novartis150